Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel modifier subfamily V member 1 (KCNV1, Kv8.1) is a neuronal subunit of the voltage-gated potassium channel family. Unlike typical channel-forming alpha subunits, Kv8.1 does not form functional ion channels on its own, but instead modifies the function of other potassium channel subunits—predominantly those of the Kv2 type—by altering their gating properties and channel kinetics. KCNV1 is expressed primarily in the brain (cerebral cortex, hippocampus, and cerebellum) and is implicated in the regulation of neuronal excitability, with particular significance for neuronal survival under stress conditions. Its (down)regulation is associated with increased vulnerability to neurodegeneration, as observed in models of amyotrophic lateral sclerosis, and genetic variation in KCNV1 is a candidate for epilepsy susceptibility.
Modulation of Kv2 channels (alters inactivation, gating, and density of Kv2.1/Kv2.2 channels); Suppression/abolition of Kv2.1, Kv2.2, and Kv3.4 channel activity at high expression levels
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel modifier subfamily V member 1 (KCNV1).